Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial
24th August 2021 Uncategorised 0Phase III study was investigating treatment for B-cell non-Hodgkin lymphoma More: Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial Source: News
read more